Evidence-based Medicine
Editorial | ChatGPT is fun, but not an author
27 Jan, 2023 | 12:20h | UTCChatGPT is fun, but not an author – Science
Related:
Tools such as ChatGPT threaten transparent science; here are our ground rules for their use – Nature
ChatGPT listed as author on research papers: many scientists disapprove – Nature
Abstracts written by ChatGPT fool scientists
The digitization and decentralization of clinical trials
26 Jan, 2023 | 12:43h | UTCThe Digitization and Decentralization of Clinical Trials – Mayo Clinic Proceedings
Analysis | Finding bias before the first patient is enrolled
26 Jan, 2023 | 12:42h | UTCFinding Bias Before the First Patient is Enrolled – Sensible Medicine
ChatGPT listed as author on research papers: many scientists disapprove
24 Jan, 2023 | 14:36h | UTCChatGPT listed as author on research papers: many scientists disapprove – Nature
Related: Abstracts written by ChatGPT fool scientists
Perspective | The case of statins, diabetes, and bias in observational studies
24 Jan, 2023 | 14:35h | UTCThe Case of Statins, Diabetes, and Bias in Observational Studies – Sensible Medicine
FDA no longer needs to require animal tests before human drug trials
24 Jan, 2023 | 14:32h | UTCFDA no longer needs to require animal tests before human drug trials – Science
See also: The FDA no longer requires all drugs to be tested on animals before human trials – NPR
Perspective | The next generation of evidence-based medicine
23 Jan, 2023 | 13:37h | UTCThe next generation of evidence-based medicine – Nature Medicine
Commentary: What does the future of clinical trials and evidence-based medicine look like? – News Medical
Commentary on Twitter
Technological advances are transforming evidence generation in medicine. For these advances to impact public health, the clinical trial landscape must evolve and adapt to keep pace, a Perspective in @NatureMedicine argues. https://t.co/5qwE1de26c pic.twitter.com/6RkJSmXXaC
— Nature Portfolio (@NaturePortfolio) January 21, 2023
SR | Mortality as a measure of treatment effect in clinical trials recruiting critically ill patients
23 Jan, 2023 | 13:27h | UTCMortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients – Critical Care Medicine (free for a limited period)
An overview of methodological considerations regarding adaptive stopping, arm dropping, and randomization in clinical trials
20 Jan, 2023 | 14:27h | UTC
Commentary from the author on Twitter
Now online in @JClinEpi (OA): https://t.co/Ton5G8x2sH
In this manuscript we provide an overview of the key methodological considerations for (multi-arm, multi-stage) clinical trials using adaptive stopping, arm dropping, and randomisation with a worked example. Details below 1/— Anders Granholm (@andersgranholm) November 16, 2022
Under a Creative Commons Attribution (CC BY 4.0) License
Abstracts written by ChatGPT fool scientists
18 Jan, 2023 | 14:29h | UTCAbstracts written by ChatGPT fool scientists – Nature
Original Study (preprint): Comparing scientific abstracts generated by ChatGPT to original abstracts using an artificial intelligence output detector, plagiarism detector, and blinded human reviewers – bioRxiv
Opinion | The American Academy of Pediatrics is pushing drugs and surgery for obesity
17 Jan, 2023 | 13:27h | UTCThe American Academy of Pediatrics is Pushing Drugs & Surgery for Obesity – Sensible Medicine
Original article and commentaries: AAP Guideline | Evaluation and treatment of children and adolescents with obesity
Analysis of questionable research practices in 163,129 randomized controlled trials
13 Jan, 2023 | 13:38h | UTC
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic
12 Jan, 2023 | 13:26h | UTC
Perspective | The limits of shared decision making
11 Jan, 2023 | 14:28h | UTCThe limits of shared decision making – BMJ Evidence-Based Medicine
Restoring mortality data in the FOURIER trial of evolocumab in patients with CVD: a reanalysis based on regulatory data
10 Jan, 2023 | 14:49h | UTCCommentaries:
Yet Another Story on Re-Analyzing a Major Trial – Sensible Medicine
Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees – TCTMD
Nature announces support for authors from over 70 countries to publish open access
10 Jan, 2023 | 14:46h | UTC
Commentary on Twitter
From today, primary research from authors from 70+ countries classified by the World Bank as low-income or lower-middle-income economies accepted for publication in @NatureMedicine or Nature research journals can be published Gold OA at no cost: https://t.co/izXuU2jLDZ
— Nature Medicine (@NatureMedicine) January 9, 2023
SR | Design and conduct of randomized clinical trials evaluating surgical innovations in ophthalmology
10 Jan, 2023 | 14:04h | UTCDesign and conduct of randomized clinical trials evaluating surgical innovations in ophthalmology: A systematic review – American Journal of Ophthalmology (free for a limited period)
ESC/AHA/ACC/WHF Joint Opinion | Randomized trials fit for the 21st century
9 Jan, 2023 | 14:44h | UTCCommentaries:
It’s Time to Revamp How Clinical Trials Are Done, Say Cardiology Societies – TCTMD
Commentary on Twitter
Together with @ACCinTouch @escardio & @worldheartfed, we are positioned to push, guide and support the remodeling of #RCTs for the 21st century. #RedesignRCTs
Read the joint statement in @circaha: https://t.co/hoypaSp10m pic.twitter.com/vwMGx0tksz
— AHA Science (@AHAScience) December 16, 2022
Review | Conducting umbrella reviews.
16 Dec, 2022 | 13:21h | UTCConducting umbrella reviews – BMJ Medicine
Perspective | The importance of long-term follow up of participants in clinical trials.
16 Dec, 2022 | 13:13h | UTCThe importance of long-term follow up of participants in clinical trials – British Journal of Cancer
Guidelines for reporting outcomes in trial protocols: The SPIRIT-Outcomes 2022 Extension.
15 Dec, 2022 | 13:46h | UTCGuidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension – JAMA (free for a limited period)
See also: Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension – JAMA (free for a limited period)
Commentary on Twitter
This Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-Outcomes 2022 extension of the SPIRIT 2013 statement provides 9 outcome-specific items that should be addressed in all trial protocols. https://t.co/OheGrTmcMh
— JAMA (@JAMA_current) December 13, 2022
Guidelines for reporting outcomes in trial reports: The CONSORT-Outcomes 2022 Extension.
15 Dec, 2022 | 13:45h | UTCGuidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension – JAMA (free for a limited period)
See also: Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension – JAMA (free for a limited period)
Commentary on Twitter
This report, the Consolidated Standards of Reporting Trials (CONSORT)–Outcomes 2022 extension, is a consensus statement on standards for reporting outcomes in clinical trial reports & contains recommendations to be integrated w the CONSORT 2010 statement. https://t.co/3cMgBmHtyE
— JAMA (@JAMA_current) December 14, 2022
Consensus Statement | Continuous glucose monitoring and metrics for clinical trials.
15 Dec, 2022 | 13:42h | UTCContinuous glucose monitoring and metrics for clinical trials: an international consensus statement – The Lancet Diabetes & Endocrinology (free registration required)
Commentary on Twitter
Online—Continuous glucose monitoring and metrics for clinical trials: an international consensus statement https://t.co/hrNXB9ycr0 #CGM #diabetes #FREE to read with registration (also FREE) #IDF2022 pic.twitter.com/x40lzAL1by
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) December 7, 2022
Comparison of clinical study results reported in medRxiv preprints vs. subsequently published peer-reviewed journal articles.
12 Dec, 2022 | 12:42h | UTCAuthor Interview: Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journals
Perspective | How to manage your time as a researcher.
8 Dec, 2022 | 12:45h | UTCHow to manage your time as a researcher – Nature